Down Syndrome - Pipeline Review, H1 2018

  • ID: 4461749
  • Drug Pipelines
  • 61 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AC Immune SA
  • Aelis Farma SAS
  • Eisai Co Ltd
  • F. Hoffmann-La Roche Ltd
  • ManRos Therapeutics
  • NeuroNascent Inc
  • MORE
Down Syndrome - Pipeline Review, H1 2018

Summary:

The latest pharmaceutical and Healthcarel and Healthcare disease pipeline guide Down Syndrome - Pipeline Review, H1 2018, provides an overview of the Down Syndrome (Genetic Disorders) pipeline landscape.

Down syndrome is a genetic disorder that causes lifelong mental retardation, developmental delays and other problems. Down syndrome varies in severity, so developmental problems range from moderate to serious. Children with Down syndrome have a distinct facial appearance. Though not all children with Down syndrome have the same features, some of the more common features are flattened facial features, small head, short neck, protruding tongue, upward slanting eyes, unusual for the child's ethnic group and unusually shaped ears. Children with Down syndrome may also have poor muscle tone, broad, short hands with a single crease in the palm, relatively short fingers and excessive flexibility.

Report Highlights:

The latest pharmaceutical and Healthcare latest pipeline guide Down Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Down Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Down Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 3, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Down Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Report Coverageproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Down Syndrome (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Down Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Down Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Down Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Down Syndrome (Genetic Disorders)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Down Syndrome (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Down Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AC Immune SA
  • Aelis Farma SAS
  • Eisai Co Ltd
  • F. Hoffmann-La Roche Ltd
  • ManRos Therapeutics
  • NeuroNascent Inc
  • MORE
Introduction

Report Coverage

Down Syndrome - Overview

Down Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Down Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Down Syndrome - Companies Involved in Therapeutics Development

AC Immune SA

Aelis Farma SAS

Eisai Co Ltd

F. Hoffmann-La Roche Ltd

ManRos Therapeutics

NeuroNascent Inc

QR Pharma Inc

Down Syndrome - Drug Profiles

ACI-24 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALZ-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAN-2401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dosmir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

minocycline hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NNI-351 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentylenetetrazol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Posiphen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-4938581 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to inhibit DYRK1A for Alzheimer's and Down Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Down Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease and Down syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit OLIG2 for Down Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy to Activate ZSCAN4 for Chromosomal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Down Syndrome - Dormant Projects

Down Syndrome - Discontinued Products

Down Syndrome - Product Development Milestones

Featured News & Press Releases

Sep 12, 2017: AC Immune Completes Recruitment For Low-Dose Cohort In World's First Clinical Trial For Anti-Abeta Vaccine Targeting Alzheimer's Disease-Like Characteristics In Individuals With Down Syndrome

Jul 11, 2017: QR Pharma Presents New Data on Posiphen in Down Syndrome at the Alzheimer's Disease International Conference

Apr 05, 2016: AC Immune Announces Publication of Ground-breaking Scientific Publication on anti-Abeta Vaccine in Preclinical Model of Down Syndrome

Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics

Feb 27, 2013: Roche Research Sheds Light On Improving Neurological Deficits In Mouse Model Of Down Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Down Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Down Syndrome - Pipeline by AC Immune SA, H1 2018

Down Syndrome - Pipeline by Aelis Farma SAS, H1 2018

Down Syndrome - Pipeline by Eisai Co Ltd, H1 2018

Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Down Syndrome - Pipeline by ManRos Therapeutics, H1 2018

Down Syndrome - Pipeline by NeuroNascent Inc, H1 2018

Down Syndrome - Pipeline by QR Pharma Inc, H1 2018

Down Syndrome - Dormant Projects, H1 2018

Down Syndrome - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Down Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AC Immune SA
  • Aelis Farma SAS
  • Eisai Co Ltd
  • F. Hoffmann-La Roche Ltd
  • ManRos Therapeutics
  • NeuroNascent Inc
  • QR Pharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll